MICIACCIA, MORENA
 Distribuzione geografica
Continente #
NA - Nord America 2.379
AS - Asia 1.387
EU - Europa 1.212
SA - Sud America 316
Continente sconosciuto - Info sul continente non disponibili 211
AF - Africa 61
OC - Oceania 27
Totale 5.593
Nazione #
US - Stati Uniti d'America 2.189
IT - Italia 649
SG - Singapore 532
CN - Cina 269
BR - Brasile 238
HK - Hong Kong 176
CA - Canada 114
RU - Federazione Russa 111
VN - Vietnam 89
DE - Germania 85
GB - Regno Unito 83
IN - India 53
BD - Bangladesh 52
SE - Svezia 52
FR - Francia 49
JP - Giappone 33
NL - Olanda 28
AU - Australia 26
CH - Svizzera 26
ID - Indonesia 25
FI - Finlandia 24
TR - Turchia 24
IL - Israele 21
AR - Argentina 20
EC - Ecuador 19
ES - Italia 17
MX - Messico 15
PL - Polonia 14
IQ - Iraq 13
KR - Corea 13
SA - Arabia Saudita 13
ZA - Sudafrica 13
BE - Belgio 12
CI - Costa d'Avorio 12
CO - Colombia 12
CR - Costa Rica 11
PH - Filippine 10
SC - Seychelles 10
UZ - Uzbekistan 10
CZ - Repubblica Ceca 9
IE - Irlanda 9
NI - Nicaragua 9
PK - Pakistan 9
CL - Cile 8
AT - Austria 7
CW - ???statistics.table.value.countryCode.CW??? 7
IR - Iran 7
LT - Lituania 7
VE - Venezuela 7
GT - Guatemala 6
PR - Porto Rico 6
SV - El Salvador 6
HU - Ungheria 5
JM - Giamaica 5
PY - Paraguay 5
TH - Thailandia 5
TW - Taiwan 5
DO - Repubblica Dominicana 4
EG - Egitto 4
KE - Kenya 4
MA - Marocco 4
MY - Malesia 4
NO - Norvegia 4
NP - Nepal 4
PE - Perù 4
UA - Ucraina 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
EE - Estonia 3
HN - Honduras 3
KZ - Kazakistan 3
LB - Libano 3
PT - Portogallo 3
SN - Senegal 3
AM - Armenia 2
BB - Barbados 2
DZ - Algeria 2
GE - Georgia 2
GR - Grecia 2
MD - Moldavia 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
TZ - Tanzania 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
AL - Albania 1
BG - Bulgaria 1
BO - Bolivia 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CY - Cipro 1
ET - Etiopia 1
FJ - Figi 1
GI - Gibilterra 1
GP - Guadalupe 1
HT - Haiti 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
Totale 5.380
Città #
Ashburn 351
San Jose 288
Singapore 269
Hong Kong 169
Council Bluffs 130
Beijing 96
Milan 90
Bari 89
Dallas 64
New York 62
Sannicandro di Bari 57
Los Angeles 54
Columbus 51
Rome 49
Chandler 48
Santa Clara 42
Nyköping 39
Fairfield 37
Ho Chi Minh City 36
Vancouver 36
São Paulo 30
Helsinki 24
Toronto 23
Cambridge 22
Tokyo 22
Boardman 21
Falkenstein 20
San Francisco 20
Frankfurt am Main 19
Munich 19
Houston 17
Lauterbourg 17
Seattle 17
Atlanta 16
London 16
Woodbridge 16
Denver 15
Naples 15
North Bergen 15
Bern 14
Jakarta 14
Buffalo 13
Catania 13
Montreal 13
Taranto 13
Abidjan 12
Hanoi 12
Phoenix 12
Brussels 11
Laval 11
Newton 11
Bitonto 10
Chicago 10
Tashkent 10
Waltham 10
Warsaw 10
Wilmington 10
Brooklyn 9
Burlington 9
Florence 9
Managua 9
New Delhi 9
Nuremberg 9
Palermo 9
Shanghai 9
Washington 9
West Lafayette 9
Brno 8
Chennai 8
Orem 8
Philadelphia 8
Santiago 8
Turin 8
Ann Arbor 7
Belo Horizonte 7
Bologna 7
Chuncheon 7
City of London 7
Guayaquil 7
Johannesburg 7
Miami 7
Palo Alto 7
San José 7
Brisbane 6
Dalmine 6
Düsseldorf 6
Illkirch-Graffenstaden 6
Jeddah 6
Lawrence 6
Lecce 6
Mersin 6
Mexico City 6
Mumbai 6
Perth 6
Prineville 6
Quito 6
Riyadh 6
Stockholm 6
Sydney 6
Willemstad 6
Totale 2.940
Nome #
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability 273
An attempt to chemically state the cross-talk between monomers of COX homodimers by double/hybrid inhibitors mofezolac-spacer-mofezolac and mofezolac-spacer-arachidonic acid 214
Novel hClpP protease activators with potential anticancer activity in DIPG patients 194
Harmaline-based scaffold as Human Caseinolytic Protease P (hClpP) inducers for Diffuse Intrinsic Pontine Glioma (DIPG) treatment 186
Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection 171
A further pocket or conformational plasticity by mapping COX-1 catalytic site through modified-mofezolac structure-inhibitory activity relationships and their antiplatelet behavior 159
MODULATORS OF HUMAN MITOCHONDRIAL PROTEASE ClpP ACTIVITY FOR PEDIATRIC DIFFUSE PONTINE GLIOMA TREATMENT 155
Cyclooxygenase-1 Inhibition: A Promising Theragnostic Approach for Ovarian Cancer 148
DECONSTRUCTING ONC201 TO DESIGN NEW MITOCHONDRIAL ClpP ACTIVATORS FOR PEDIATRIC H3K27-ALTERED DIFFUSE MIDLINE GLIOMA 141
STRUCTURAL EVOLUTION OF ONC201-DERIVED COMPOUNDS TARGETING THE MITOCHONDRIAL PROTEASE CLPP FOR PEDIATRIC DIFFUSE MIDLINE GLIOMA H3K27-ALTERED" 138
Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders 138
Fluorescent imaging probes for in vivo ovarian cancer targeted detection and surgery 129
Three-dimensional structure of human cyclooxygenase (hCOX)-1 125
Three-dimensional structure of human cyclooxygenase (hCOX)-1 125
Comparative Structural Analysis of hCOX‑1 and oCOX‑1 Isoenzymes 121
Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes 120
Repurposing of natural origin compounds as HsClpP inducers to treat diffuse midline glioma (DMG) 115
Neuroinflammation and Microglial Constitutive COX-1 Inhibition 113
m-Terphenylamines, Acting as Selective COX-1 Inhibitors, Block Microglia Inflammatory Response and Exert Neuroprotective Activity 112
Ovine COX-1 Isoenzyme Bio-production 112
COX-1 INHIBITORS AS ANTI-PLATELET AGENTS IN COVID-19 111
Patient Bone Marrow Aspiration to Explore the Cyclooxygenases (COXs) Involvement in Multiple Myeloma 111
Human Caseinolytic Protease P (hClpP) Activity Modulating Agents For The Treatment Of DIPG/DMG 109
Harmaline to Human Mitochondrial Caseinolytic Serine Protease Activation for Pediatric Diffuse Intrinsic Pontine Glioma Treatment 109
A Simplified Direct O2 Consumption-Based Assay to Test COX Inhibition 109
Pediatric Diffuse Midline Glioma H3K27-Altered: From Developmental Origins to Therapeutic Challenges 107
TARGETING HUMAN MITOCHONDRIAL ClpP AS A NOVEL THERAPEUTIC APPROACH TO H3K27-ALTERED DIFFUSE MIDLINE GLIOMA 107
CHALLENGE TRANSABILITY OF “IN VITRO” TO “IN VIVO”: GENE-EXPRESSION BIOMARKERS AND FLUORESCENT IMAGE-GUIDED SURGERY PROBES IDENTIFICATION FOR OVARIAN CANCER 107
Modulation of the activity of human mitochondrial protease complex ClpXP as potential therapeutic strategy for cancer 103
DIPG-27. Diffuse Intrinsic Pontine Glioma (DIPG) challenge: from gene expression profile to drug. 101
Structure-activity relationships of piperazine-2-one derivatives as novel human ClpP activators 96
Learning from Nature: From a Marine Natural Product to Synthetic Cyclooxygenase-1 Inhibitors by Automated De Novo Design 89
Inside circular economy challenges: “green” application to valorise olive mill wastewater 87
Design and synthesis of new [4,5-b] and [4,5-c] imidazopyridines as potential fluorophores/inhibitors for Human Cyclooxygenase-1. 86
Mitochondrial Protease ClpP: Cancer Marker and Drug Target 82
Decoding Gene Expression Changes in Cerebral Tumors: Before and After Radiotherapy 82
The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel mediated resistance in gastric cancer cell lines 80
The Tyrosine Kinases Inhibitors (TKI) Staurosporine/Midostaurin Act as Cation Channel Inhibitors with Antiproliferative Effects in DIPG36 and DIPG50 cells 78
Structural simplification of imipridones to speed up the knowledge on the nature of the interactions with the human ClpP, a mitochondrial protease strictly linked to DIPG 78
Can Focused Ultrasound Overcome the Failure of Chemotherapy in Treating Pediatric Diffuse Intrinsic Pontine Glioma Due to a Blood–Brain Barrier Obstacle? 76
KATP Channel Inhibitors Reduce Cell Proliferation Through Upregulation of H3K27ac in Diffuse Intrinsic Pontine Glioma: A Functional Expression Investigation 72
Potassium channels and TRPV1 modulators on SU-DIPG-36 and SU-DIPG-50 cells: in vitro effects and channel currents characterization 71
ONC201-derived Tetrahydropyridopyrimidindiones as powerful ClpP protease activators to tackle diffuse midline glioma 69
Exosomes in Ovarian Cancer: Towards Precision Oncology 69
Harmaline as novel mitochondrial human ClpP activator for the treatment of pediatric DIPG 60
Effect of microbial fermentation on functional traits and volatiloma profile of pâté olive cake 58
Olive Mill Wastewater Fermented with Microbial Pools as a New Potential Functional Beverage 57
Therapeutic Role of Cyclooxygenase-1 (COX-1) Inhibition, Challenging the Conventional View of COX-1 as Purely Constitutive 56
Triazole-benzodiazepine derivatives: One-pot synthesis, characterization, hirshfeld surface analysis, and computational insights into anticancer potential as KIF11 inhibitors 47
Leveraging multitargeting BChE-MAO B inhibitors against microglia-related neuroinflammation: in vitro biological evaluation, structure-activity relationships, drug-like properties, and X-ray crystal complexes 38
Size-Controlled Mesoporous Silica Nanoparticles via Template Nanoarchitectonics from a Deferoxamine Derivative for Enhanced Blood–Brain Barrier Permeability and Neuroprotective Chelation Therapy 33
Actions of Midostaurin as Cation Channel and Tyrosine Kinase Inhibitor in Diffuse Intrinsic Pontine Glioma Cell Lines 26
TARGETING HUMAN MITOCHONDRIAL ClpP: A THRILLING CHALLENGE FOR NEW THERAPEUTIC STRATEGIES IN H3K27-ALTERED DIFFUSE MIDLINE GLIOMA 19
Dysregulation of Human ClpP Using Small Molecules with Piperazine-Based Scaffold for Diffuse Intrinsic Pontine Glioma Therapy Validated by Patient-Derived Tumor Organoids 13
Elucidating the Molecular Impact of DA29‐Induced ClpP Chemoactivation on Mitochondrial Function 6
N-Adamantyl-1-Pentyl-4-Oxo-1,4-Dihydroquinoline-3-Carboxamide and N-(Adamantan-1-Yl)-2-(Alkyloxy)benzamide Derivatives as Fluorescent Probes for Selective CB2R Targeting 2
Totale 5.593
Categoria #
all - tutte 20.332
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.332


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202256 0 0 0 0 2 5 2 14 3 8 9 13
2022/2023152 8 19 17 6 18 21 4 27 19 4 6 3
2023/2024295 4 14 14 24 26 18 16 7 95 35 16 26
2024/2025924 41 14 40 35 68 78 150 86 47 60 88 217
2025/20262.723 274 105 183 263 333 154 299 126 363 273 164 186
2026/20271.236 255 134 286 502 59 0 0 0 0 0 0 0
Totale 5.593